Innovent secures NRDL inclusion for seven innovative therapies

Innovent Biologics, Inc. announced that seven of its innovative products, including a new indication for TYVYT (sintilimab injection) and the first-time inclusion of SYCUME (teprotumumab N01 injection), have been added to China's 2025 National Reimbursement Drug List (NRDL). The updated NRDL will become effective on January 1, 2026, broadening patient access and affordability for these medications.

The newly listed drugs cover critical disease areas, primarily oncology and cardiovascular and metabolic diseases. Key inclusions are Limertinib, Dupert (fulzerasib), DOVBLERON (taletrectinib), Retsevmo (selpercatinib), and Jaypirca (pirtobrutinib). These additions are expected to benefit more individuals and families across China by making high-quality medicines more accessible.

The new TYVYT indication, in combination with fruquintinib, targets advanced endometrial cancer patients, addressing a critical treatment gap. SYCUME, China's first approved IGF-1R antibody drug, is listed for moderate-to-severe thyroid eye disease, redefining treatment standards and meeting long-unmet needs in China. Innovent remains committed to patient-centered care and enhancing drug affordability and accessibility.